Riskpilot← Back to searchSign inGet full accessGXP-PHARMA SUPPORT ApS
APSActiveCVR 36033347Energivej 3Engineering activities and related technical consultancy · NACE 7112Est. 20141 employeeswww.gxp-pharmasupport.dk
Revenue 2025
DKK 129K
-149% vs 2024
EBITDA margin
-307.8%
-14% vs 2024
Equity ratio
29.7%
Financial strength
Net profit 2025
DKK -314K
-89% vs 2024
| Revenue | DKK 129K | -149% |
| EBITDA | DKK -396K | -14% |
| Net profit | DKK -314K | -89% |
| Total assets | DKK 198K | -69% |
| Equity | DKK 59K | -84% |
| Employees | 1 | — |
Legal name
GXP-PHARMA SUPPORT ApS
CVR number
36033347
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
3. juli 2014
Share capital
DKK 20.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse, bestyrelsesformanden eller af den administrerende direktør alene.
Company purpose
Selskabets formål er salg og udvikling af undervisning, konsulentassistance og inspektioner indenfor det farmaceutiske område og anden efter ledelsen relevant beslægtet virksomhed.
Address
Energivej 3
Phone
+4550300270
Email
JL@gxp-pharmasupport.dk
Website
www.gxp-pharmasupport.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1.095 | 211 | 361 | -263 | 129 |
| Staff expenses | -0 | -0 | -0 | -0 | -524 |
| EBITDA | 153 | -58 | 127 | -348 | -396 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 153 | -58 | 127 | -348 | -396 |
| Net financials | 395 | -382 | 344 | 134 | 26 |
| Profit before tax | 548 | -440 | 471 | -213 | -370 |
| Tax | 122 | -95 | 104 | -47 | -55 |
| Net profit | 426 | -346 | 367 | -166 | -314 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2.177 | 1.105 | 1.481 | 646 | 198 |
| Equity | 1.118 | 772 | 1.140 | 373 | 59 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.059 | 332 | 341 | 273 | 139 |
| Total debt | 1.059 | 332 | 341 | 273 | 139 |
EBITDA margin
-307.8%
This company
15.8%
Market median
-2048% vs market
20212025
Equity ratio
29.7%
This company
38.2%
Market median
-22% vs market
20212025
Return on equity
-535.3%
This company
18.4%
Market median
-3009% vs market
20212025
Net profit margin
-244.7%
This company
8.1%
Market median
-3121% vs market
20212025
Asset turnover
0.65×
This company
1.12×
Market median
-42% vs market
20212025
Debt / equity
2.37×
This company
0.62×
Market median
-282% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LC Chief Executive Officer | Chief Executive Officer | 2014 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2014 | |
| Chairman | 2014 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CHRIBEN ApS
GXP-PHARMA SUPPORT ApS Board members of GXP-PHARMA SUPPORT ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lone Cleveland Andersen | Chief Executive Officer | 0 companies |
| Iben Cleveland Laursen | Board of Directors | 0 companies |
| Jan Laursen | Chairman | 0 companies |